Explainer-Who is eligible for the new FDA-approved Alzheimer’s drug?

By Deena Beasley The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen’s Leqembi for patients with Alzheimer’s disease. The FDA decision is expected to trigger broader coverage of the $26,500-a-year drug by the U.S. government’s Medicare health plan for people aged 65 and older. Leqembi was granted “accelerated” FDA…

Read More

Biden administration did not sanction unofficial talks with Russians, State Dept says

WASHINGTON (Reuters) -President Joe Biden’s administration did not sanction or support secret meetings that former top U.S. national security officials held with Russian Foreign Minister Sergei Lavrov and other Russians on potential talks to end the Ukraine war, the White House and State Department said on Thursday. NBC News reported that the former U.S. officials…

Read More

Meta takes aim at Twitter with Threads app, millions join

(Corrects grammar in first paragraph) By Katie Paul NEW YORK (Reuters) -Meta Platforms on Wednesday launched a direct challenge to Twitter with Threads, garnering millions of users in hours as it sought to take advantage of its rival’s much-weakened state after a series of chaotic decisions from owner Elon Musk. Those quick to join the…

Read More

Rivian must face lawsuit claiming it defrauded IPO investors over vehicle prices

By Jonathan Stempel (Reuters) – A federal judge said Rivian Automotive must face a lawsuit claiming it defrauded shareholders during and after its blockbuster 2021 initial public offering by concealing that had underpriced its electric vehicles, leading to unpopular price hikes. U.S. District Judge Josephine Staton in Los Angeles said shareholders could try to prove…

Read More